- Medical - Instruments & Supplies
- Healthcare
-
6.95
EPS
-
31.96
P/E
-
32.6B
MARKET CAP
-
0.86%
DIV YIELD
Company Overview
9001 SPECTRUM CENTER BLVD.,SAN DIEGO CA 92123,8587462400
CEO
Mr. Michael J. Farrell BE, MBA, SM
Employess
9980
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Website
https://www.resmed.com
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Next Earnings Date
Oct. 24, 2024
Ex Dividends date
Sep. 19, 2024
Dividend Date
Aug. 15, 2024
YTD Performance
29.28%
Fiscal Year End
06-30
IPO Date
1995-06-02
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 11.66% | 12.44% | 13.59% | 10.95% |
| EPS | 11.02% | 19.65% | 28.51% | 13.40% |
| Equity | 10.71% | 18.61% | 19.01% | 17.78% |
| Cash | -12.50% | 10.13% | -6.89% | 4.59% |
| Return On Capital (ROIC) | 15.28% | 17.27% | 18.36% | 19.96% |
Debt
| year (millions) | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Short Term Debt | 35.2 | 31.8 | 31.8 | 35.6 | 33.2 |
| Long Term Debt | 697 | 1,550 | 886 | 758 | 1,270 |
| LT Finance Leases | 141 | 139 | 142 | 138 | 123 |
| Shares Outstanding | 147 | 147 | 146 | 145 | 144 |
| Market Cap | 27,500 | 32,100 | 30,600 | 35,800 | 27,700 |
Price
News
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
1 monthWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
RMD ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ResMed Inc. investment
1 monthNEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
accesswire.com
ResMed Shares Breathing Life into Big Money Portfolios
1 monthLeading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.
fxempire.com
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.
1 monthNEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
accesswire.com
ResMed (RMD) CEO on GLP-1 Drugs: "This is a Really Exciting Moment for Global Healthcare System"
1 month@ResMedAmericas CEO Michael Farrell joins Oliver Renick to talk about the rise of GLP-1 drugs and its impact on the CPAP Therapy. He also discusses A.I.
youtube.com
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
1 monthThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
ATTENTION RMD SHAREHOLDERS: Investors who lost money on ResMed Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
1 monthNEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
accesswire.com
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.
1 monthNEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
accesswire.com
ResMed Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - RMD
1 monthNEW YORK, NY / ACCESSWIRE / August 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
accesswire.com
An Investigation Has Commenced on Behalf of ResMed Inc. Shareholders. Contact Levi & Korsinsky to Discuss your RMD Losses
1 monthNEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
accesswire.com
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
2 monthsResMed Inc. RMD reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion.
benzinga.com
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand
2 monthsResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.
zacks.com